FDA Wants Your Take on Patient Drug Meeting Impacts
Published Date: 5/1/2026
Notice
Summary
The FDA wants to hear from patients, advocates, and drug developers about how past patient-focused drug meetings have helped shape medicine and research. They’ve opened a public comment period until June 30, 2026, to collect stories and ideas that could improve future drug development. This is a great chance for anyone involved in healthcare to share their experience and influence how new treatments are made—no cost to participate, just your voice!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA opens PFDD public docket
The FDA has created a public docket (Docket No. FDA-2026-N-3947) to collect examples of how past patient-focused drug development (PFDD) meetings affected community engagement, research priorities, advocacy strategies, medical product development programs, and clinical practice. Patients, caregivers, family members, patient advocates, medical product developers, healthcare providers, and academic researchers are invited to submit examples and stories to help inform future drug development and research.
Comment deadline and confidentiality rules
Comments must be submitted by June 30, 2026 (electronic submissions accepted via https://www.regulations.gov until 11:59 p.m. Eastern Time that day, or written/paper submissions received by that date at Dockets Management Staff, FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852). Comments posted to the docket will be publicly viewable unless submitted as a confidential written/paper submission; confidential submissions require two copies (one marked confidential and one redacted copy for public posting).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-08523 — Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Some companies want to become bank holding companies or buy banks, and the Federal Reserve is checking their applications. If you have thoughts, you can send comments by June 1, 2026. This affects banks in South Dakota, Nebraska, and Texas, and could shake up who controls these banks soon.
Next: 2026-08525 — Agency Information Collection Extension
The Department of Energy is extending its loan application form for advanced vehicle tech for three more years. This affects companies applying for these special loans and keeps the process going without extra costs or changes. If you want to share your thoughts, make sure to comment by June 1, 2026!